Effects of fibric acid derivatives and metformin on postprandial lipemia

Atherosclerosis

Volumn 141, Issue SUPPL. 1, 1998, Pages

  Weintraub, M S ^a   Charach, G ^a   Grosskopf, I ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Chylomicron remnants; Chylomicrons; Fibric acid; Metformin; Postprandial lipoproteins

Indexed keywords

BEZAFIBRATE; CHYLOMICRON; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPOPROTEIN; METFORMIN; RETINOL PALMITATE; TRIACYLGLYCEROL;

ADULT; AREA UNDER THE CURVE; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; GLUCOSE INTOLERANCE; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MALE; POSTPRANDIAL STATE; PRIORITY JOURNAL;

EID: 0031744137     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(98)00221-4     Document Type: Conference Paper

References (33)

1. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb 1990;11:1-14.
2. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62:707-14.
3. Miller NE, Thelle DS, Forde OH, Mjos OD. The Tromso Heart Study. High density lipoprotein and coronary heart disease: A prospective case-control study. Lancet 1977;1:965-7.
4. Goldbourt U, Medalle JH. High density lipoprotein cholesterol and incidence of coronary heart disease - The Israeli Ischemic Heart Disease Study. Am J Epidmiol 1979;109:296-308.
5. Stout RW. The relationship of abnormal circulatory insulin to atherosclerosis. Atherosclerosis 1977;27:1-13.
6. Nikkilae EA, Miettinen TA. Plasma insulin in coronary artery disease. Lancet 1965;2:508-11.
7. Alaupovic P, Hodis HN, Knight-Gibson C, Mack WJ, LaBree L, Cashin-Hemphill L, et al. Effects of lovastatin on apo A- and apo B-containing lipoproteins: families in a subpuplations of patients participating in the Monitored Atherosclerosis Regression Study (MARS). Arterioscler Thromb 1994;14:1906-14.
8. Patsch JR, Miesenböck G, Hopfewieser T, Mühlberger V, Knapp E, Dunn JK, et al. Relation of triglyceride metabolism and coronary artery disease: studies in the postprandial state. Arterioscler Thromb 1992;12:1336-45.
9. Ryu JE, Howard G, Craven TE, Bond MG, Hagaman AP, Grouse JR III. Postprandial triglyceride and carotid atherosclerosis in middle-aged subjects. Strock 1992;23:823-8.
10. Glomset JA. The Plasma lecithin cholesterol acetyltransferase reaction. J Lipid Res 1968;9:155-67.
11. Patsch JB, Karlin JB, Scott LW, Smith LC, Gotto AM Jr. Inverse relationship between blood levels of high density lipoprotein subfraction-2 and magnitude of postprandial lipemia. Proc Natl Acad Sci USA 1983;80:1449-53.
12. Zilversmit DA. Athergenesis. A postprandial phenomenon. Circulation 1979;60:473-85.
13. Morganroth J, Levi RL, Fredricksen DS. The biochemical, clinical and genetic features of type III hyperlipoproteinemia. Ann Intern Med 1975;82:158-64.
14. Kane JP, Chen GC, Hamilton RL, Hardman DA, Malloy MJ, Havel RJ. Remnants of lipoprotein of intestinal and hepatic origin in familial dysbetalipoproteinemia. Arteriosclerosis 1983;3:47-56.
15. Eisenberg A. High density lipoprotein metabolism. J Lipid Res 1984;25:1017-58.
16. Pyorala K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 1979;2:131-41.
17. Orchard TJ, Becker DJ. Plasma insulin and lipoportein concentrations: an atherogenic association. Am J Epidemiol 1983;118:326-7.
18. Laakso M, Sarlund H. Insulin resistance in association with lipid and lipoprotein abnormalities in subjects with varying degrees of glucose tolerance. Atherosclerosis 1990;10:223-31.
19. Gin H, Messerschmidt C. Metformin improved insulin resistance in type I insulin dependent diabetic patients. Metabolism 1985;34:923-5.
20. Nosadini R, Avogaro A. Effects of metformin on insulin stimulated glucose turnover and insulin binding to receptors in type II diabetes. Diabetes Care 1987;10:62-7.
21. Hazzard WR, Bierman EL. Delayed clearance of chylomicrons remnants following vitamin A-containing oral fat load in broad-B disease (type III hyperlipoproteinemia). Metabolism 1976;25:777-801.
22. Wilson DE, Chan I, Ball M. Plasma lipoprotein retinoides after vitamin feeding in normal man. Minimal appearance retinyl esters among low-density lipoproteins. Metabolism 1983;32:514-7.
23. Berr F, Kern F Jr. Plasma clearance of chylomicrons labelled with retinyl palmitate in healthy human subjects. J Lipid Res 1984;25:805-12.
24. Weintraub MS, Eisenberg S, Breslow JL. Different patterns of postprandial metabolism in normals and type IIa, type III and type IV hyperlipoproteinemics: Effect of treatment with cholestyramine and gemfibrozil. J Clin Invest 1987;79:1110-9.
25. Stender S, Zilversmit DA. Arterial influx of esterified cholesterol from two plasma lipoprotein fractions and its hydrolysis in vivo in hypercholesterolemic rabbits. Atherosclerosis 1981;39:97-109.
26. Stender S, Zilversmit DA. Comparison of cholesteryl ester transfer from chylomicrons and other plasma lipoproteins to aorta intima-medial of cholesterol-fed rabbit. Arteriosclerosis 1982;2:493-9.
27. Grundy SM, Mok HYI. Hylomicron clearance in normal and hyperlipidemic man. Metab Clin Exp 1976;25:1225-39.
28. Manninen V, Elo MO, Frick MH. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. J Am Med Assoc 1988;260:641-1.
29. Bianchi R, Erkelens DW. Role of insulin resistance in human disease. Diab Nutr Metab 1994;7:43-51.
30. Polonsky KS, Given BD, Hirsch L, Shapiro ET, Tillil H, Beebe C, et al. Quantitative study of insulin secretion and clearance in normal obese subjects. J Clin Invest 1988;81:435-41.
31. Polonsky K, Sturis J, Bell G. Non-insulin-dependent diabetes mellitus-a genetically programmed failure of the beta cell to compensate for insulin resistance. New Engl J Med 1996;334:777-83.
32. Jeppsen J, Zhou MY, Chen YDI, Reaven GM. Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM. Diabetes Care 1994;17:1093-9.
33. Giuliano D, De Rosa N, Di Maro G, Marfella R, Acampora R, Buoninconti R, D'Onofrio F. Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care 1993;16:1387-90.